- Clone:
- REA168 | Z27.3.7
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC, MC Glossary
- Select a conjugate:
- Select a size:
Related products for CD158e1/e2 Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD158e1/e2 (REA168) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD158e1/e2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD158e1/e2 antibodies and with a suitable counterstaining. As a control, CD158e1/e2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD158e1/e2 (REA168). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REA168 recognizes the CD158e1/e2 antigens, which are single-pass type I membrane proteins. CD158e is expressed on CD56dimCD16+ natural killer (NK) cells and CD8+ T cells. Killer cell immunoglobulin-like receptors (KIRs) contribute to the regulation of NK cell–mediated cytotoxicity. The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long or short cytoplasmic domain. According to the length of their cytoplasmic tail, KIRs can be further subdivided into inhibitory KIRs and activating KIRs. The CD158e1 antigen is also known as KIR3DL1 (KIR, three Ig like domain extracellular domains, long cytoplasmic tail, 1) and the CD158e2 antigen as KIR3DS1 (KIR, three extracellular Ig like domains, short cytoplasmic tail, 1). Within the KIR3DL1/S1 gene locus, CD158e2 represents a conserved allelic variant and displays unique features in comparison to the highly polymorphic CD158e1 allele. CD158e1 provides an inhibitory signal of NK cell lytic activity upon interaction with its specific ligand, HLA-Bw4. Despite the lack of formal evidence for an interaction of CD158e2 with HLA-Bw4 or any other HLA class I subtype, a growing number of associations between the presence of CD158e2 and the outcome of viral infections have been described. Especially, the potential protective role of CD158e2 in combination with HLA-Bw4-I80 in the context of HIV-1 infection has been studied intensively.
Additional information: Clone REA168 displays negligible binding to Fc receptors.
KIR3DL1, KIR3DS1, HLA-BW4-specific inhibitory NK cell receptor, MHC class I NK cell receptor, Natural killer-associated transcript 3 (NKAT-3, NKAT3), p70 natural killer cell receptor clones CL-2/CL-11 (p70 NK receptor CL-2/CL-11), KIRp70/NKB1
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.